We therefore reasoned that deoxygalactonojirimycin (DGJ), which is clinically approved as the pharmacological chaperone Migalastat that helps mutant forms of the GH27 α-galactosidase GalA that are found in Fabry disease patients to fold more efficiently and traffic to the lysosome [22,23], should bind similarly well to MYORG. The gene discussed is GLA; the disease is Fabry disease.